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The past two decades have witnessed a striking paradigm
shift with respect to our understanding of the widespread
effects of aldosterone. There is substantive evidence
that mineralocorticoid receptor (MR) activation promotes
myriad ‘off target’ effects on the heart, the vasculature, and
importantly the kidney. In the present review, we summarize
the expanding role of MR activation in promoting both
vascular and renal injury. We review the recent clinical
studies that investigated the efficacy of MR antagonism
(MRA) in reducing proteinuria and attenuating progressive
renal disease. We also review in-depth both the utility and
safety of MRA in the end-stage renal disease (ESRD) patient
undergoing dialysis. Because the feasibility of add-on MRA is
critically dependent on our ability to minimize or avoid
hyperkalemia, and because controversy centers on the
incidence of hyperkalemia, we critically review the risk of
hyperkalemia with add-on MRA. Our present analysis
suggests that hyperkalemia supervening in MRA-treated
patients is overstated. Furthermore, recent studies
demonstrating the efficacy of new non-absorbed, orally
administered, potassium [Kþ ]-binding polymers suggest
that a multi-pronged approach encompassing adequate
surveillance, moderate or low-dose MRA, and K-binding
polymers may adequately control serum K in both chronic
kidney disease and ESRD patients.
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Aldosterone is a steroid hormone with mineralocorticoid
activity that is produced primarily by the adrenal glome-
rulosa in response to diverse stimuli including angiotensin II,
adrenocorticotropic hormone, and importantly increased
serum potassium (K) levels.
Aldosterone binds to the cytosolic mineralocorticoid
receptor (MR), a member of the nuclear hormone receptor
family, in the distal convoluted tubule of the kidney.
According to the traditional formulation, the major physio-
logical role of aldosterone is to increase sodium reabsorption
in the distal nephron in order to maintain sodium balance
and volume homeostasis. Reabsorption is mediated via
activation of the apical epithelial sodium channel (ENaC)
and the basolateral Naþ , KþATPase. Aldosterone enhances
the expression of the gene that encodes the a-subunit of
ENaC. Aldosterone influences the apical targeting and
function of ENaC through diverse regulatory pathways
involving the serine/threonine protein kinase, serum- and
glucocorticoid-regulated kinase 1 and the ubiquitin ligase
Nedd4-2.
Since its isolation and characterization almost 60 years
ago, clinicians and medical investigators have perceived
aldosterone primarily as acting at the level of the kidney to
regulate extracellular fluid volume and K metabolism—the
‘traditional or classical theory’. The past two decades have
witnessed a striking paradigm shift with respect to our
understanding of the widespread effects of aldosterone.
Consequently, these myriad ‘off target’ actions of aldosterone
have mandated an expansion and major revision of the
traditional concept of aldosterone’s role.1–5 There is sub-
stantive and ever increasing evidence that aldosterone
impacts the heart, the vasculature, the central nervous
system, and the kidney, and that it can promote vascular
remodeling, collagen formation, and endothelial dysfunc-
tion.4,5 Aldosterone has been shown to have rapid non-
genomic effects, where signaling through the classic pathways
of gene activation, transcription, and protein synthesis are
not required. Therefore, the nongenomic responses may be
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rapid. These actions contribute substantively to the patho-
physiology of congestive heart failure and progressive renal
dysfunction. Furthermore, there is now compelling evidence
that MR activation produces hypertension by promoting
a direct vasoconstrictor effect on the vascular wall and by
acting in the circumventricular region of the hypo-
thalamus.1–5 All of these new insights have spurred intense
investigative interest in evaluating the use of MR antagonist
(MRA) as a new treatment strategy for controlling blood
pressure (BP) and reducing albuminuria/proteinuria and for
possibly retarding the progression of chronic renal disease.3
Although the explosive growth in this field has prompted
publication of several recent reviews,3,6,7 the breadth and
expanse of this subject has prompted an in-depth considera-
tion of several themes and topics with a relative paucity of
discussion of other topics that we believe are critically
important. Consequently, our review is meant to comple-
ment these earlier publications and to highlight several
salient points that require critical consideration.
In this overview, we will summarize the expanding role of
aldosterone/MR activation and the potential mechanisms by
which it promotes both vascular and renal injury. It is
becoming increasingly evident that these effects, occurring
independently of hemodynamic factors, contribute substan-
tively to enhanced cardiovascular risk and progressive renal
disease. We will review the preclinical and clinical studies that
investigated the use of MRA using either spironolactone
(SPL) or the selective MRA eplerenone (EPL) to attenuate
progressive renal disease. We will conclude with a discussion
of some of the clinical implications of utilizing MR blockade
in patients with incipient nephropathy as well as the possi-
bility that this treatment regimen may be beneficial in
patients with stage 5 chronic kidney disease (CKD).
As full doses of renin–angiotensin system blockers
including angiotensin-converting enzyme (ACE) inhibitors
and angiotensin receptor blockers (ARBs) attenuate but do
not abrogate progression of renal dysfunction,8–11 add-on
MRA therapy constitutes a rational therapeutic strategy for
retarding progression of renal disease. Furthermore, because
the feasibility of add-on MRA is critically dependent on our
ability to minimize or avoid the risk of hyperkalemia, and
because great controversy centers on the incidence and
magnitude of hyperkalemia,12,13 we will also critically review
the scientific data relating to the risk of hyperkalemia with
add-on MRA.
Another patient cohort that comprises a substantive
portion of CKD patients, are patients whose primary disorder
is resistant hypertension. Consideration of MRA treatment is
often ignored in this patient cohort, because the presence of
the renal disease is often overshadowed by the immediacy of
the primary diagnosis of resistant hypertension. Indeed,
although MRA treatment of these patients with resistant
hypertension with concomitant CKD is clearly indicated as
the appropriate add-on treatment, its use is frequently and
inappropriately withheld because of the overriding fear of
inducing hyperkalemia in the setting of CKD. In this review,
we address this issue and propose that greater attention be
devoted to this large hypertensive cohort that inappropriately
is undertreated with MRA.
We will conclude our review by considering an issue that
has both immediacy and yet is frequently ignored—the
‘elephant in the room’. Patients with CKD and end-stage
kidney disease (ESRD) die of cardiovascular events.14–17
Consequently, the CKD and ESRD patient is enriched with
respect to susceptibility to adverse cardiovascular outcomes,
the very patient who theoretically stands to benefit most
from add-on MRA. This therapeutic intervention is con-
strained by the palpable and widespread concern regarding
provoking hyperkalemia in the ESRD patient. Consequently,
we plan to rigorously examine the available data base in
ESRD patients in order to demonstrate that the risk for
developing hyperkalemia is significantly less than previously
thought, and that instituting MRA in ESRD patients with
appropriate laboratory surveillance is a reasonable treatment
option.
HOW THE ALDOSTERONE PARADIGM HAS CHANGED
MARKEDLY: A PLATFORM FOR FORMULATING RATIONAL
THERAPEUTICS
As detailed by John Funder in a recent review,1 a reasonable
summary of the prevailing view of aldosterone and the MR in
1990 posited that: (a) angiotensin was the major determinant
of aldosterone secretion, (b) aldosterone is the physiologic
ligand for MR, (c) that aldosterone elevates BP by its sodium-
retaining effects with consequent volume expansion, (d)
MRAs act by blocking the binding of aldosterone to MR, and
(e) aldosterone acts genomically and nongenomically.
After 20 years, we realize that the majority of these
concepts are wrong.18,19 It is now accepted that: (a)
angiotensin does not constitute the major driver of
aldosterone secretion, (b) aldosterone is merely one of the
physiological ligands for MR, (c) although aldosterone’s
sodium-retaining effects are relevant in defending volume
homeostasis in the setting of hypovolemia, aldosterone raises
BP primarily by actions on the vasculature and central
nervous system. An understanding of this new paradigm for
aldosterone constitutes a rational framework for examining
the therapeutic potential of MRA in hypertension, CKD, and
ESRD.
An understanding of the interaction between aldosterone
and the MR is necessary to fully comprehend the new
paradigm. The MR is order of magnitude more sensitive to
cortisol than to aldosterone. This paradox has been clarified
in part by the demonstration by Funder and Myles20 that
the action of 11-beta-hydroxysteroid dehydrogenase-2 was
to debulk intracellular glucocorticoid levels, reducing them
from 100- to 10-fold those of aldosterone, but not that
of metabolizing glucoocorticoids out of existence. Conse-
quently, most epithelial MRs are thus occupied by the
approximately 10-fold preponderance of cortisol over
aldosterone, but are not activated. The mechanism whereby
cortisol-occupied MR remains inactive remains to be defined.
956 Kidney International (2012) 81, 955–968
rev iew L Shavit et al.: Aldosterone blockade and the MR in the management of CKD
Recent studies by Schiffrin have delineated the mechanisms
underlying crosstalk between Ang II type 1 receptor and MR.
They have demonstrated that the nongenomic and genomic
effects of aldosterone are differentially dependent on activity
of both Ang II type 1a receptor and Ang II type 1b receptor,
thereby providing a mechanistic understanding for the
benefit of combination therapy with dual blockade of Ang
II type 1 receptor and MR to treat hypertension and
progression of heart and kidney failure.21
Expansion of the classical concept to the new paradigm is
characterized by several additional features that subtend
aldosterone’s role in promoting target organ damage. First in
the presence of high-salt (HS) intake, aldosterone produces
persistent hypertension with consequent BP-dependent target
organ damage. Second, in a permissive milieu with attendant
high-sodium intake, even normal concentrations of aldoster-
one produce BP–independent target organ damage acting
through inflammatory and pro-fibrotic pathways.5,19,20,22
Metabolic effects of aldosterone/MR activation
Emerging evidence also supports a paradigm shift in our
understanding of aldosterone’s ability to promote insulin
resistance and participate in the pathogenesis of the
metabolic syndrome and dysglycemia.23–25 Recent data
suggest that excess circulating aldosterone promotes the
development of both disorders by impairing insulin meta-
bolic signaling, which in turn leads to insulin resistance.
Indeed, hyperaldosteronism is associated with impaired
pancreatic b-cell function, skeletal muscle insulin sensitivity,
and elevated production of proinflammatory adipokines
from adipose tissue, which results in systemic inflammation
and impaired glucose tolerance.
Accumulating evidence indicates that the cardiovascular
and renal abnormalities associated with insulin resistance are
mediated in part by aldosterone acting on the MR. Although
we have known that MR blockade attenuates cardiovascular
and renal injury, only recently have we learned that MR
blockade improves pancreatic insulin release, and insulin-
mediated glucose utilization.
POTENTIAL MECHANISMS BY WHICH MR ACTIVATION/
SIGNALING PROMOTES FIBROSIS AND RENAL INJURY
Accumulating data indicate that in addition to angiotensin II,
aldosterone/MR signaling is also a key mediator of kidney
injury. Although the precise mechanisms remain incomple-
tely defined, aldosterone/MR is shown to possess deleterious
effects on non-aldosterone-sensitive distal tubule cells in the
kidneys, such as podocytes. An enhanced MR effector
mechanism is closely related to protein leakage from the
kidneys,26–29 a strong risk factor for progression of CKD.
Clinical studies have also revealed that MR blockade is highly
effective in reducing urinary protein excretion.3 In addition,
experimental studies by Shibata et al.28 have demonstrated
the unequivocal benefits of a MRA, EPL, in ameliorating
proteinuria and glomerular podocyte damage. It has been
postulated that aldosterone/MR activation induces apoptosis
or alters the adhesive capacity of podocytes. As these cells
are highly differentiated and are considered to lack
proliferative capacity, the reduction in the numbers of
podocytes causes denudation of the glomerular basement
membrane and adhesion to Bowman’s capsule, a common
pathway leading to glomerulosclerosis. MR is known to be
present in other kidney cells, including mesangial cells and
renal fibroblasts, and to modulate their functions via
profibrotic action or alteration of cell cycle regulators. In
addition, aldosterone activates nuclear factor-kB in principal
cells of the cortical collecting duct through mechanisms that
involve serum- and glucocorticoid-regulated kinase 1.
Nuclear factor-kB regulates inflammation and transepithelial
sodium transport, so these observations suggest a convergence
of sodium reabsorption and inflammatory stimulation in the
collecting duct. In accord with these experimental data, clinical
observations demonstrate that subjects with aldosterone over-
production manifest a high incidence of renal dysfunction.30,31
Moreover the panoply of these cellular effects could be relevant
in the pathogenesis of kidney injury in hypertensive patients
with increased aldosterone/MR activity.3
HS (‘INAPPROPRIATE SALT’) STATE ENHANCES RENAL
INJURY AND VASCULAR INFLAMMATORY EFFECTS OF MR
ACTIVATION
A fact that remains puzzling is the intensifying role of a HS/
volume environment for the deleterious effects of aldosterone
in the cardiovascular system and the kidney. A ‘HS’ state
facilitates the deleterious effects of MR activation.22 Seventy
years ago, in a seminal study, Hans Selye demonstrated
that when he administered deoxycorticosterone acetate to
a rodent model with partial renal ablation, a HS intake (3%
saline) was required to elicit striking vascular inflammatory
changes in the heart and the kidney.32 Recent studies in the
Dahl salt-sensitive rats have suggested that HS diet induces
oxidative stress thereby promoting MR activation in the
kidney. The implications of these observations are relevant
for both an understanding of the pathogenesis of MR–
induced renal injury, and a platform for formulating a
rational treatment regimen for conferring renal beneficial
effects in the CKD patient and diabetic nephropathy.
This formulation is supported by studies demonstrating
that aldosterone-induced injury is prevented or ameliorated
by dietary sodium restriction suggesting that sodium
restriction affects the balance of positive and negative effects
induced by aldosterone.33 Mechanistically, when ingesting a
liberal sodium intake, acute aldosterone administration
reduces phosphorylated extracellular nitric oxide synthetase
(which is vascular protective) and increases phosphorylated
extracellular signal-regulated kinases 1 and 2 and protein
kinase C (deleterious to the vasculature). In contrast, dietary
sodium restriction increases phosphorylated extracellular
nitric oxide synthetase and decreases phosphorylated extra-
cellular signal-regulated kinases 1 and 2 and protein kinase C
basally, and minimizes or reverses their responses to acute
aldosterone administration.
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This relationship becomes clinically relevant when patients
display plasma aldosterone levels that are inappropriate for
the amount of dietary salt consumption or the magnitude of
intravascular volume. Patients presenting any degree of
volume retention or those consuming a HS diet should
demonstrate low levels of circulating aldosterone.
CIRCULATING ALDOSTERONE AND THE KIDNEY
In analogy with the heart, recent evidence has accrued
indicating that intrarenal aldosterone may modulate changes
in the kidney independent of circulating aldosterone
levels. Xue and Siragy34 have recently demonstrated the
presence of aldosterone synthase gene, CYP11B2 mRNA and
protein in the renal cortex of normal rats, and its
upregulation by angiotensin II and low-salt intake. The
presence of a local renal autocrine or paracrine aldosterone
system suggests that aldosterone blockade may be efficacious
in conferring benefit even in the absence of elevated plasma
aldosterone.
Xue and Siragy34 have also demonstrated the upregulation
of renal aldosterone synthase in a model of insulin-deficient
diabetes with hyperglycemia. Furthermore, this increase in
aldosterone synthase was partially reversed by the correction
of the elevated blood glucose levels by insulin administration.
Although the role of renally produced aldosterone has not yet
been elucidated, it is tempting to speculate that a system in
which aldosterone production and its receptors exist in close
proximity, is capable of modulating renal structure and
function may contribute to the initiation or progression of
not only diabetic nephropathy, but perhaps non-diabetic
kidney disease. Collectively, the emerging studies suggest that
aldosterone plays a significant autocrine or paracrine role in
the heart and in the kidney.
ARE MEASUREMENTS OF CIRCULATING ALDOSTERONE
HELPFUL AS A GUIDE FOR INITIATING MRA?
As in congestive heart failure, measurements of circulating
aldosterone levels may not be helpful in deciding when to
prescribe MRAs. It is now clear that MRs are present not only
in epithelial cells of the kidney, colon, and salivary and sweat
glands, but also in epithelial and nonepithelial tissues
including the heart, brain, and blood vessels.3–5,18 Moreover,
extra-adrenal synthesis of aldosterone in these same tissues
has been documented, and a localized paracrine role has been
proposed. Consequently, the deleterious effects of aldoster-
one in promoting progressive renal injury may occur in the
absence of discernible elevations of aldosterone. As suggested
by Funder,1 measurements of circulating aldosterone levels
may not be helpful in suggesting whether to initiate MRA
treatment.
CLINICAL STUDIES ASSESSING THE USE OF MRAs IN CKD
CKD affects 25 to 30 million Americans and many millions of
people across the globe in both developed and developing
nations.35–38 A number of treatment options have been
shown to delay the progression of kidney damage.9–11
To date, the major therapeutic intervention to delay the
progression of CKD and the risk of ESRD has encompassed
the use of renin–angiotensin system blockers including ACE
inhibitors (ACEis) and ARB agents, and more recently direct
renin inhibitors. These agents have become standard of care
in proteinuric CKD patients.9–11,39,40 Both ACEi and ARB
significantly reduce proteinuria and the risk of ESRD by
about 20 to 30%. But this shortfall is suboptimal in the
context of the major costs and burden of ESRD.35,36
Consequently, this has spurred the initiation and conduct
of many studies to explore additional interventions to
countervail or mitigate the traditional and nontraditional
risk factors for CKD.41–44 In the past decade, several
investigators have investigated the effects of adding an
MRA to either ACEi or ARBs in an attempt to amplify the
renal protective effects of renin–angiotensin system blockers.
These investigations have focused on the endpoints of
proteinuria, and stabilizing renal function.
For the purposes of this review, we included studies
enrolling any patient with CKD stages 1 to 4 with albumin-
uria or proteinuria. Studies of CKD secondary to both dia-
betic and non-diabetic CKD were included. Studies enrolling
patients with CKD stage 5 (glomerular filtration rate (GFR)
o15ml/min per 1.73m2) and/or receiving hemodialysis
(HD) or other forms of renal replacement therapy will be
considered in a separate section (vide infra). We included
studies of MRA (both selective and nonselective antagonists)
administered with ACEi or ARB or both that were adminis-
tered for at least 4 weeks. Results are summarized in Table 1.
The following outcome measures were analyzed: (a) end
of treatment urinary albumin/protein excretion (24-h
proteinuria or 24-h albuminuria in g/day); (b) renal function
measured as end of treatment GFR (ml/min or ml/min per
1.73m2); and (c) effects on serum K, including instances of
hyperkalemia (defined as serum K 45.5mEq/l or mmol/l),
and (d) sexual adverse effects including gynecomastia or
breast pain, and impotence.
Clinical studies assessing the effects of add-on of MRAs
to ACEi and/or ARB in CKD stages 1 to 4 are summarized
in Table 1. To date, we have reviewed 23 published studies
of which 9 were published only in abstract form and
1 represents animal data and consequently is not included.
In the remaining 13 studies, 2 are review and/or meta
analyses.45,46
A total of 728 patients in 11 clinical trials were included.
Nine trials (424 patients) compared non-selective aldosterone
antagonists plus ACEi and/or ARB with ACEi and/or ARB
alone.47–55 One trial encompassing 268 patients with type 2
diabetes mellitus, albuminuria, hypertension, estimated GFR
(eGFR) 460ml/min per 1.73m2 and K p5.0mmol/l,
compared selective MRA’s (either EPL 50mg, EPL 100mg,
or placebo) with enalapril 20mg.56 One recent retrospective
study included 32 patients with SPL and 4 patients with EPL
added-on ACEi and/or ARB alone.57 To our knowledge, there
are no studies that compared aldosterone antagonists alone
with placebo (without ACEi and/or ARB).
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TRIAL CHARACTERISTICS
Seven studies included diabetic patients;48,50–53,55,56 whereas
the large study of Bianchi et al.47 included patients with
various forms of glomerulonephritis. Two additional studies
included patients with non-diabetic renal disease encom-
passing immunoglobulin A nephropathy, benign nephro-
sclerosis, and membranous nephropathy.49,54 A single study
examined the long-term effects of MRAs in subjects with
resistant hypertension associated with CKD stage 3 (eGFR
30–59ml/min per 1.73m2).57
All studies excluded patients with GFRp30ml/min per
1.73m2. Baseline albuminuria/proteinuria ranged from 0.8
to 3.6 g/day. Of the 10 studies that analyzed the efficacy of
nonselective MRA’s, 3 compared SPL plus ACEi with ACEi
alone48,50,55 whereas 7 compared SPL plus ACEi and/or ARB
with ACEi and/or ARB alone.47,49,52–54
In all studies, 25mg/day of SPL was used throughout the
study period except for the study of van den Meiracker
et al.,50 which used SPL 25 to 50mg/day. Study duration
varied from 2 to 20 months. Sample size ranged from 18
to 268. None of the studies were powered to detect hard
primary outcomes including mortality or long-term renal
outcomes. Ten studies reported the change in 24-h protein-
uria or albuminuria as the primary end point,47–56 while one
reported effects of MRAs on resistant hypertension.57 In the
study of Epstein et al.56 that analyzed the role of selective
MRA, patients with type 2 diabetes were studied and the
change in urinary albumin–creatinine ratio and serum Kwere
the primary outcome measures.
TRIAL OUTCOMES
End of treatment 24-h proteinuria
There was a significant reduction in 24-h proteinuria with
SPL plus ACEi and/or ARB (9 clinical trials, 424 patients)
compared with ACEi and/or ARB alone.47–55 A significant
reduction in proteinuria was detected also with the use of
EPL plus ACEi in comparison with ACEi plus placebo at the
end of 12-week period (1 trial, 268 patients).56
End of treatment GFR
Data for end of treatment GFR was available in 8 studies
(6 randomized controlled trials, 326 patients with SPL,
1 randomized controlled trial, 268 patients with EPL,
1 retrospective study, 36 patients).46,48,50–53,56,57 There was
no significant difference in GFR with either SPL or EPL plus
ACEi and/or ARB compared with ACEi and/or ARB alone.
However, the retrospective study on subjects with resistant
hypertension and CKD stage 3 revealed statistically signi-
ficant increment of serum creatinine (from 1.5±0.3 to
1.8±0.5mg/dl) and decrement of eGFR (from 48.6±8.7 to
41.2±11.5ml/min per 1.73m2) because of use of MRAs.57
End of treatment BP
There was a significant reduction in systolic BP with SPL
along with ACEi and/or ARB compared with ACEi and/or
ARB alone (7 randomized controlled trials, 372 patients). At
12 weeks, there was a significant reduction in end of treat-
ment systolic and diastolic BP with EPL plus ACEi in compa-
rison with ACEi plus placebo arm.56 In patients with resistant
hypertension, MRAs induced a significant decrease in systolic
and diastolic BP (from 162±22 to 138±14mmHg and from
87±17 to 74±12mmHg, respectively).57
Hyperkalemia
Although all the studies reported data on the changes in
serum K, only one study specified the frequency for measure-
ments for serum K.56 On the one hand, nine studies
(472 patients) reported a significant increase in the risk of
hyperkalemia with MRAs administered in combination
with ACEi and/or ARB compared with ACEi and/or ARB
alone.47–52,54,55,57 In contrast, the study of Epstein et al.56
carefully assessed the incidence of hyperkalemia by determin-
ing serum K at baseline and every 2 weeks during the 12-week
study. They determined the incidences of both sustained
hyperkalemia (serum K 45.5mmol/l on two consecutive
occasions 1- to 3-day apart) and severe hyperkalemia (serum
K 46.0mmol/l on any occasion). No significant effect on
serum K with EPL plus ACEi compared with ACEi alone was
demonstrated in 268 diabetic patients.56 Recent post hoc
analysis of this study revealed only 5 separate instances in
1260 separate K determinations in the EPL groups with either
severe or sustained hyperkalemia. Furthermore, hyperkalemia
did not correlate with eGFR.58
Gynecomastia
Gynecomastia was an infrequent complication in both
patients on low-dose SPL or placebo groups. Bianchi
et al.47 reported that 6 out of 83 patients developed gyneco-
mastia (only 1 patient warranting discontinuation of medi-
cation and 5 patients with mild gynecomastia) in the SPL
group but none (out of 82 patients) in the placebo arm.47
Furamatsu et al.49 reported 1 of 15 patients who developed
gynecomastia in the SPL group that did not require
discontinuation of therapy. Pisoni et al.57 reported two
patients with breast tenderness without gynecomastia or
impotence.
MRA TREATMENT IN PATIENTS WITH RESISTANT
HYPERTENSION AND CONCOMITANT CKD
Another patient cohort that comprises a substantive portion
of CKD patients, are patients whose primary disorder is
resistant hypertension. Consideration of MRA treatment is
often ignored in these discussions, because the presence of
the renal disease is often overshadowed by the immediacy
of the primary diagnosis of resistant hypertension. Indeed
although MRA treatment of these patients with resistant
hypertension with concomitant CKD is clearly indicated as
the appropriate add-on treatment, its use is frequently and
inappropriately withheld because of the overriding fear of
inducing hyperkalemia in the setting of CKD. Recently,
Pisoni et al.57 retrospectively evaluated the long-term effects
and safety of MRAs added to a pre-existing antihypertensive
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regimen in 36 patients with resistant hypertension and stage
3 CKD (32 patients on SPL, 4 on EPL, median follow-up of
312 days). MRAs induced a significant decrease in systolic BP
from 162±22 to 138±14mmHg (Po0.0001) and in
diastolic BP from 87±17 to 74±12mmHg (Po0.0001).
Serum K increased from 4.0±0.5 to 4.4±0.5mEq/l
(P¼ 0.0001), with the highest value being 5.8mEq/l. Some
worsening of renal function was detected (the serum creati-
nine increased from 1.5±0.3 to 1.8±0.5mg/dl (P¼ 0.0004)
and the eGFR decreased from 48.6±8.7 to 41.2±
11.5ml/min per 1.73m2 (P¼ 0.0002). The authors concluded
that MRAs significantly reduce BP in subjects with resistant
hypertension associated with stage 3 CKD, although close
biochemical monitoring is recommended because of an
increased risk of hyperkalemia and worsening of renal
function.
CLINICAL STUDIES ASSESSING THE USE OF MRAs IN ESRD
Both the ‘Randomized Aldactone Evaluation Study’ (RALES)
and recent ‘Eplerenone in patients with systolic heart failure
and mild symptoms’ (EMPHASIS-HF) studies conclusively
demonstrated that low-dose MRA (SPL and EPL, respec-
tively) when added to optimal treatment results in additional
reductions in overall mortality and the rate of death from
cardiovascular causes.59,60 As the prevalence of heart disease
is extremely high in patients with advanced CKD and
comprise up to 50% of deaths in ESRD patients,61 the
potential benefit of MRA cannot be overestimated in this
patient population. However, the widespread clinical use of
these drugs in ESRD is currently limited because of concern
that they may provoke clinically significant hyperkalemia.
This concern is generally based on an older study in which
anephric HD patients were treated with very high doses of
SPL (300mg/day) and a subsequent study showing an
increased risk of developing hyperkalemia in HD patients
treated by ACE inhibitors or ARBs.62,63
Recent studies have demonstrated that the beneficial
cardiovascular effects of MRAs are achieved at much lower
doses in both non-CKD, and probably in CKD populations.
In this section, we will critically examine currently available
scientific data regarding the use of MRAs in ESRD with
specific emphasis on the risk, incidence and magnitude of
hyperkalemia. Results are summarized in Table 2.
In 2003, two prospective open-label clinical studies
evaluated the safety of low-dose SPL in chronic HD patients.
Saudan et al.64 administered SPL to 14 HD patients at an
initial dose of 12.5mg three times per week for 2 weeks and
then increased the dose to 25mg three times per week for an
additional 2 weeks.
Plasma K did not change in the SPL group during the
entire study period. During the baseline period, 12.5mg
period, 25mg period and the wash-out period, plasma K
levels were 5±0.4, 4.9±0.4, 4.9±0.3, and 4.9±0.4mEq/l,
respectively, in the SPL group, and 4.8±0.8, 4.9±0.7,
4.9±0.7, and 4.6±0.7mEq/l in the control group. In a
multivariate analysis adjusted for baseline K, SPL treatment
was associated with a modest reduction in plasma K
(–0.2mEq/ml, Po0.016).
Similar results were reported by Hussain et al.65 They
studied fifteen HD outpatients with mean plasma K
o5.6mEq/l who were treated with SPL 25mg daily for 28
days. Plasma K was measured before every HD during the
study. The mean K level was 4.6±0.6mEq/l at baseline and
4.9±0.9mEq/l at study completion. Nine patients completed
the trial with plasma K levels o5.6mEq/l, requiring no
adjustments in the HD prescription. Four patients had
plasma K levels between 5.6 and 6.0mEq/l. Dialysate K was
decreased by 1.0mEq/l in two of these patients. One patient
developed hyperkalemia (7.6mEq/l) on day 20 of treatment
and SPL was discontinued.
Michea et al.66 published an elegant study designed to
evaluate the effects of a 2-week course SPL (50mg three times
weekly) on the extrarenal regulation of K measured by the
expression of Naþ -channel (ENaC a-subunit) in peripheral
blood mononuclear cells, in six chronic anuric HD patients.
No patients developed hyperkalemia during the SPL treat-
ment period. HD patients had significantly higher mRNA of
the a-subunit of ENaC compared with lymphocytes from
normal subjects (Po0.05). In all HD patients studied, SPL
treatment for 2 weeks significantly decreased the amount of
ENaC a-subunit mRNA (Po0.05 vs. pre-drug treatment).
An additional compelling issue studied by clinical
investigators was whether long-term low-dose SPL was safe
in HD patients with heart failure and whether this inter-
vention improves cardiovascular function without inducing
hyperkalemia. Taheri et al.67 enrolled 16 patients with
moderate-to-severe heart failure (14 patients with New York
Heart Association class 4 and 2 patients with New York Heart
Association class 3 heart failure) in a double-blind rando-
mized placebo-controlled study: one group of 8 patients
received 25mg of SPL after each dialysis session for 6
months, and the remainder received a placebo. Echocardio-
graphy was performed on all the patients to assess ejection
fraction and left ventricular mass at 12 h after completion of
HD, both at the beginning and the end of study. Plasma K
was measured pre-dialysis every 4 weeks. SPL had a signi-
ficant positive effect on ejection fraction and a mean left
ventricular mass of the treated patients. There was an increase
in mean ejection fractions from 31.3±8.76 to 41.2±9.6 in
the SPL group (P¼ 0.01), whereas it did not change in the
placebo group (33.7±9.1 to 35.0±7.7, P40.05). The ejection
fraction increased more in SPL-treated group than in the
placebo-treated group 6.2±1.64 vs. 0.83±4.9, 95% confidence
interval (0.19 to 6.35), P¼ 0.046. Left ventricular mass
decreased from 158±16.1 g/m2 to 142±15.4 g/m2 (P¼ 0.02)
in the SPL group, whereas the placebo group showed a trend
to increase from 158±12.6 g/m2 to 159±13.5 g/m2 (P¼ 0.2).
The difference of mean left ventricular mass between the SPL
and the placebo group was statistically significant 8.4±
4.72, vs. 3.0±7.97, 95% confidence interval (8.04 to 3.68),
P¼ 0.021. Plasma K concentration of the placebo group
was higher than those of the SPL group at the baseline
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(4.66±0.41 vs. 3.86±0.34, 95% confidence interval (1.13
to 0.47), P¼ 0.001), but both groups reached the same level
of plasma K after the second month and remained similar
until the end of study. Hyperkalemia developed in only one
patient, in the placebo group, at the sixth month.
An additional relatively large study examined 61 oligo-
anuric HD patients treated with SPL at a dose of 25mg/day
during a 6-month period.68 The average K level at baseline
was 4.96±0.72mEq/l (range 3.8–6.4), while these levels at 2
weeks, 4 weeks, 2 months and 6 months after the SPL
treatment were 5.16±0.82 (3.0–6.7), 5.14±0.68 (3.6– 6.4),
5.26±0.76 (3.3–6.7), and 5.18±0.72 (3.6–6.7)mEq/l, respec-
tively. The plasma K levels during treatment were higher than
those at baseline, but did not increase with time and never
attained levels exceeding 6.8mEq/l.
A recent randomized controlled trial established new
aspects of positive effects of prolonged low-dose MRAs on
vascular injury in the setting of ESRD.69 In all, 53 age- and
sex-adjusted patients were randomly assigned to receive
50mg SPL or placebo thrice weekly after dialysis during 2
years and their carotid intima-media thickness was measured.
Measurements of carotid intima-media thickness after
2 years showed a progression in the placebo group, whereas
in the SPL group a significant decrease or even a reversal of
carotid intima-media thickness was observed. Progression
rates (mm/year) were: common carotid, placebo: 0.06±0.07,
SPL: 0.01±0.04; carotid bifurcation, placebo: 0.15±0.27,
SPL: 0.0001±0.01; internal carotid, placebo: 0.10±0.12,
SPL: 0.10±0.15. No significant differences in plasma K
were observed between the two groups, except for months 23
and 24. Final analyses showed a slight tendency to increased
K levels by 0.012 mEq/l per month during SPL vs. placebo
administration.69
The effect of MRA on the BP of chronic HD patients was
the primary end point of two clinical investigations that
provided novel innovative information to our understanding
of the mechanism by which aldosterone can contribute to the
development of hypertension. Oligoanuric dialysis patients
constituted a unique clinical model to study the effects of
MRA on BP that occurred independent of their diuretic/
natriuretic properties. Gross et al.70 performed a rando-
mized, double-blind, placebo-controlled study in which eight
HD patients were administered either SPL, 50mg, or placebo
orally twice daily for 2 weeks. This was followed by a
crossover design comprising a 3-week washout period, after
which patients crossed over in their treatment arms for an
additional 2 weeks. Administration of SPL for 2 weeks
decreased pre-dialysis systolic BP from 142.0±19.6 to
131.4±18.2mmHg (Po0.05) without a concomitant effect
on pre-dialysis and post-dialysis plasma K, aldosterone
concentrations, or plasma renin activity.
In all the above previously described studies, SPL was
utilized as the MRA. In contrast, a recent study by Shavit
et al.71 used EPL, a selective MRA, in the HD setting. In this
trial, EPL was administered to eight anuric (mean urinary
volume 70±106 cc per 24 h) HD patients at a dose of 25mg
twice daily for 4 weeks. This MRA regimen produced a
decrease in pre-dialysis systolic BP from 166±14 to
153±10mmHg (Po0.05) whereas EPL had no effect on
diastolic BP. There was no change in urinary volume,
intradialytic changes in body weight, K, pre-dialysis weight,
plasma aldosterone or PRA. Pre-dialysis plasma K level was
4.67±0.2mEq/l before commencement of EPL and increased
to 4.79±0.55 after 2 weeks (P¼ 0.611) and to 4.86±0.38 at
the end of 4 weeks of EPL administration (P¼ 0.48).
Importantly, none of these patients manifested a K of
6mEq/l. The demonstration of a substantive reduction in
systolic BP in the absence of a concomitant increase in
either urinary volume or sodium excretion indicates that the
mechanism of action was extrarenal. Consequently, it is
probable that a direct effect of EPL on the heart, the
vasculature, or central nervous system could explain the
effect of MRA to decrease BP in these anuric HD patients.
A recent report by Ritz72 may be relevant. A fast inter-
action between aldosterone and its receptor on endothelial
cells was illustrated by the nanotechnique of atomic force
microscopy.73 This interaction induces endothelial cell
stiffness, raises cell volume, and reduces deformability thus
affecting vascular compliance.73 Consistent with this finding,
SPL, added to chronic ACE inhibition, improves endothelial
function.74,75 These experimental and clinical data support
the possibility that improved endothelial function might be
the major mechanism involved in the improvement in BP in
HD patients following MRA administration.
In conclusion, currently available data regarding use of
low-dose MRA in chronic HD suggest that the risk for
developing hyperkalemia is significantly less than previously
thought, and that consequently administering MRAs to
ESRD patients with appropriate laboratory surveillance may
constitute a safe and effective therapeutic intervention. In
addition, although some of these patients experienced a
modest elevation of plasma K,65 its functional significance, as
assessed by electrocardiographic verification, clinical signs
and symptoms of hyperkalemia, was not evident. Our review
of recent data demonstrates that MRA lowers BP, and
concomitantly confers beneficial effects on carotid intima-
media thickness, left ventricular ejection fraction and
hypertrophy in patients with chronic HD, in analogy with
what has recently been widely demonstrated in the general
population. In concert, these observations constitute a
platform for initiating clinical trials assessing the influence
of MRA on ‘hard’ clinical outcomes in ESRD patients,
including overall and cardiovascular mortality.
MRA INTERVENTIONS IN PATIENTS ON PERITONEAL DIALYSIS
There is paucity of information on MRA interventions in
peritoneal dialysis patients. Hausmann et al.76 describes a
case report of a peritoneal dialysis patient who received SPL
25mg daily without ACE inhibitors, beta-blockers or digoxin
for moderately decreased systolic left ventricular function
(ejection fraction 32%) and a significant degree of diastolic
dysfunction. Echocardiography was repeated 10 months after
964 Kidney International (2012) 81, 955–968
rev iew L Shavit et al.: Aldosterone blockade and the MR in the management of CKD
SPL treatment had been initiated. The ejection fraction had
increased from 32 to 46%, with no change in left ventricular
diameter and hypertrophy. Although impaired diastolic rela-
xation was still apparent, left ventricular filling pressure was
normalized reflecting improved diastolic function. The effect
of SPL on BP was not reported in this case report. The serum
K level was monitored weekly for 1 month and then monthly
for 10 months and did not exceed 5.1mEq/l in the pre-treat-
ment period and 5.5mEq/l during the period of SPL therapy.
A second publication merely entails a Letter to the Editor
without data on either left ventricular function or BP.77 These
few fragmentary reports emphasize the need for prospective
studies in ESRD patients treated with peritoneal dialysis to
delineate the effects of treatment with MRA.
HYPERKALEMIA AS A CONSTRAINT FOR MRA THERAPY IN
CKD PATIENTS
Although mineralocorticoid antagonists have been demon-
strated to be highly efficacious in patients with heart failure
and hypertension, especially resistant hypertension, the risk
of hyperkalemia must be considered.
Following publication of the RALES study, several
subsequent studies presented evidence from clinical practice
that was disturbing. These studies alleged that the frequent
use of SPL in patients with heart failure after the publication
of RALES study was associated with an increased risk of
hyperkalemia compared with that reported in the RALES
study. In a widely cited population-based study, Juurlink
et al.78 reported an increased SPL-prescription rate for
patients treated with ACE inhibitors who had been
hospitalized for heart failure (3.4% in early 1994 vs. 14.9%
in late 2001, Po0.001).78 The rate of hospitalization for
hyperkalemia rose from 2.4 per 1000 patients in early 1994 to
11 per 1000 patients in late 2001 (Po0.001), and the rate of
associated mortality rose from 0.3 per 1000 patients in early
1994 to 2 per 1000 patients in late 2001 (Po0.001), with no
significant change in the overall rate of hospitalization for
heart failure over this time.
In a population-based study, Masoudi et al.79 analyzed the
SPL-prescription rate in patients 465 years of age who had
heart failure. The SPL-prescription rate increased after the
publication of the RALES study from 3 to 21.3%
(Po0.0001). It is important to note, however, that 30.9%
of these prescriptions given after the publication of RALES
were for patients who did not meet the inclusion criteria of
the RALES study. These exclusion criteria included older age,
non-cardiovascular comorbidities, discharge to skilled nur-
sing facilities, and care that was provided by physicians who
lacked board certification. In a third study by Bozhurt et al.,80
the increased risk of hyperkalemia after SPL prescription was
associated with less intensive follow-up and the use of MRAs
by primary care providers.
Regretfully, many confounders qualify the applicability of
several of these studies. In the Juurlink study,78 there were no
direct measures of K or creatinine, adherence to medications,
use of nonprescription drugs, and the clinical details
surrounding death. Indeed, many of the patients hospitalized
for hyperkalemia may have died of another illness. The
diagnostic coding for hyperkalemia has not been validated;
moreover, many patients hospitalized for hyperkalemia may
have also had volume contraction or renal insufficiency
related to SPL therapy. In addition, the authors were
unable to identify adverse outcomes that occurred before
admission.
Subsequent studies have provided a different perspective.
Pitt et al.81 published an analysis of serum K levels and
clinical outcomes in the Eplerenone Post-Acute Myocardial
Infarction Heart Failure Efficacy and Survival Study (EPHE-
SUS) trial. Compared with placebo, the incidence of
hyperkalemia (defined as Kþ 45.5mmol/l) was higher
(11.2 vs. 15.6%, Po0.001) and the incidence of hypokalemia
(Kþ o3.5mmol/l) was lower (13.1 vs. 8.4%, Po0.001) in
patients treated with EPL. Hyperkalemia occurred mostly in
the first 30 days of the study. It should be emphasized that the
enhanced risk of hyperkalemia occurred despite treatment
with a relatively low dose of EPL (25mg per day initially,
titrated to a maximum of 50mg per day during a mean
follow-up of 16 months). Their analysis identified several
predictive factors for developing hyperkalemia including
eGFR o60ml/min per 1.73m2, history of diabetes mellitus,
and elevated baseline serum K (Kþ 44.3mmol/l).
An additional large trial assessing this issue was ‘Eplerenone
in patients with systolic heart failure and mild symptoms,
EMPHASIS-HF’, which randomly assigned 2737 patients
with New York Heart Association class II heart failure to
receive EPL (up to 50mg daily) or placebo, in addition to
recommended therapy.60 During the course of the study, 188
patients (13.8%) receiving EPL and 222 patients (16.2%)
receiving placebo discontinued the study drug because of an
adverse event (P¼ 0.09). At 1 month, the mean change in
serum creatinine level from baseline was 0.15±0.35mg/dl in
the EPL group, as compared with 0.07±0.29mg/dl in the
placebo. At 1 month, the mean change in K level from
baseline was 0.16±0.51mEq/l in the EPL group, as compared
with 0.04±1.16mEq/l in the placebo group (P¼ 0.001). At
the trial cut-off date, K levels had increased from baseline by
0.16±0.56 and 0.05±0.53mEq/l, respectively (Po0.001 for
both comparisons). A serum K level above 5.5mEq/l was
reported in 158 of 1336 patients (11.8%) in the EPL group
and 96 of 1340 patients (7.2%) in the placebo group
(Po0.001). A serum K level above 6.0mEq/l occurred in
33 of 1336 patients (2.5%) in the EPL group and 25 of 1340
patients (1.9%) in the placebo group (P¼ 0.29).
A recent post hoc analysis58 of an earlier study on 268
patients with type 2 diabetes mellitus, albuminuria, hyper-
tension, eGFR 460ml/min per 1.73m2, and Kp5.0mmol/l
at entry who received enalapril 20mg plus either EPL 50mg,
EPL 100mg, or placebo for 12 weeks56 assessed both the
incidence of sustained or severe hyperkalemia or whether
eGFR predicts hyperkalemia. Only five patients in the two
EPL groups manifested severe (serum K 46.0mEq/l on
any occasion) or sustained (serum K 45.5mEq/l on two
Kidney International (2012) 81, 955–968 965
L Shavit et al.: Aldosterone blockade and the MR in the management of CKD rev iew
consecutive occasions) hyperkalemia, and hyperkalemia did
not correlate with eGFR.
Khosla et al.82 have reported on the predictors of
hyperkalemia when an MRA is added to a renin–angiotensin
system blocker regimen. They studied patients with resistant
hypertension and stages 2 or 3 CKD and reported that the
predictors of hyperkalemia included a baseline eGFR of
p45ml/min per 1.73m2 in whom baseline serum K was
44.5 mEq/l on appropriately dosed diuretics.
Although our present analysis (see above) suggests that the
complication of hyperkalemia supervening in patients treated
with MRA is overstated, recent investigative efforts with a
new non-absorbed, orally administered, potassium [Kþ ]-
binding polymer (RLY5016) may facilitate adequate control
of this potential complication.83 Pitt et al.83 recently reported
on the results of the PEARL-HF trial, the first prospective,
placebo-controlled, double-blind trial of RLY5016 to prevent
hyperkalemia in chronic HF patients receiving standard
therapy, including an ACEi or ARB and a beta-adrenergic-
blocking agent in addition to SPL 25–50mg/day. Patients
were randomized to double-blind treatment with 30 g/day
RLY5016 or placebo for 4 weeks. SPL, initiated at 25mg/day,
was increased to 50mg/day on day 15 if Kþ wasp5.1mEq/l.
The end points included the change from baseline in serum
Kþ at the end of treatment (primary); the proportion of
patients with hyperkalemia (Kþ 5.5mEq/l); and the propor-
tion titrated to SPL 50mg/day. At the end of treatment,
compared with placebo, RLY5016 had significantly lowered
serum Kþ levels with a difference between groups of
0.45mEq/l (Po.001); a lower incidence of hyperkalemia
(7.3% RLY5016 vs. 24.5% placebo, Po0.015). In patients
with CKD (N¼ 66), the difference in Kþ between groups
was 0.52mEq/l (Po0.031), and the incidence of hyperka-
lemia was 6.7% RLY5016 vs. 38.5% placebo (Po0.041).
There were no drug-related serious adverse events. Hypoka-
lemia (Ko3.5mEq/l) occurred in 6% of RLY5016 patients vs.
0% of placebo patients (Po0.094).83 This demonstration
that RLY5016 prevented hyperkalemia and was relatively well
tolerated in patients with HF receiving standard therapy and
SPL (25–50mg/day) suggests that it may constitute an
efficacious treatment for successful mitigation or prevention
of hyperkalemia produced by MRA added-on to ACEi or
ARBs in CKD patients. It should be noted, however, that this
polymer has not yet been approved for clinical use.
Additional studies are required to delineate the efficacy of
this new resin in CKD patients and ultimately in CKD stages
3 and 4.
SEX-HORMONE–RELATED SIDE EFFECTS OF
MINERALOCORTICOID ANTAGONISTS
Non-selective MRAs
SPL is an effective MRA but can provoke undesirable sexual
side effects leading to its discontinuation. This phenomenon
results from non-selective binding of SPL to androgen and
progesterone receptors and includes gynecomastia, breast
pain, menstrual irregularities, impotence, and decreased
libido. The RALES trial highlights both the frequency of
sexual side effects of MRA, and its impact in impairing
compliance.59 This study included 1663 patients with
heart failure who were randomly assigned to placebo or
a single daily dose of SPL (25 to 50mg daily). Candidates
were excluded if they had a serum creatinine concentration
42.5mg/dl (221 mmol/l) or a serum K concentration
45.0mEq/l. SPL was generally well tolerated. Gynecomastia
or breast pain was reported by 10% of the men in the SPL
group and 1% of the men in the placebo group (Po0.001),
causing more patients in the SPL group than in the placebo
group to discontinue treatment (10 vs. 1, P¼ 0.006).59 SPL
did not induce additional side effects in respiratory,
metabolic, urinary, skin, gastrointestinal, or central nervous
system compared with placebo.
Selective MRAs
EPL is a competitive antagonist of the MR and is an effective
and selective MRA. In EPL, 17-a-thoacetyl group of SPL is
replaced with a carbomethoxy group, conferring excellent
selectivity for the MR over other steroid receptors.84 Thus,
EPL possess an advantage over SPL because it produces few if
any significant and debilitating sexual side effects.
In the EPHESUS trial, safety of EPL (25mg per day
initially, titrated to a maximum of 50mg per day during a
mean follow-up of 16 months) was evaluated in 3307 patients
treated with EPL and 3301 placebo-treated patients.85 The
overall incidence of adverse events reported with EPL
(78.9%) was similar to placebo (79.5%). Adverse events
occurred at a similar rate regardless of age, gender, or race.
Patients discontinued treatment because of an adverse event
at similar rates in either treatment group (4.4% EPL vs. 4.3%
placebo), with the most common reasons for discontinuation
being hyperkalemia, myocardial infarction, and abnormal
renal function. The rates of sex-hormone–related adverse
events as gynecomastia, mastodynia, abnormal vaginal
bleeding was 0.5% in EPL and 0.6% in the placebo groups.
EMPHASIS-HF60 trial was consistent with these results and
did not demonstrate increased sex-hormone–related adverse
events related to EPL therapy.
FUTURE PERSPECTIVES
Patients with CKD and ESRD, at the present time, die
primarily because of cardiovascular events. As the CKD and
ESRD patient has an enhanced susceptibility to adverse
cardiovascular outcomes, these patients theoretically stand to
benefit the most from add-on MRA. To date this therapeutic
intervention has been constrained by the compelling and
widespread concern regarding the risk of producing hyper-
kalemia. In this review, we have demonstrated that MRA
therapy in low doses suffices to produce the desired
antialbuminuric effect. Our current review confirms that
the risk for developing hyperkalemia in both CKD and ESRD
patients is significantly less than previously thought, and that
instituting MRA in ESRD patients with appropriate labora-
tory surveillance may be a reasonable treatment option.
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Finally, we advocate that prospective randomized studies
with careful surveillance of serum K be initiated to test the
hypothesis that an even lower dose of MRA (o50mg EPL or
12.5mg SPL) can confer beneficial effects on the kidney in
terms of proteinuria and on the heart in terms of fatal
cardiovascular events. If such studies are positive, they may
constitute a theoretical framework for investigations to test
the efficacy and safety of very low-dose MRA therapy in
patients with CKD stages 3 and 4 as well as those on dialysis.
To paraphrase John Funder,1 the more answers we obtain in
the arena of MR and the kidney, we are challenged by ever
more questions. The next few years promise to be engaging
and fulfilling for investigators and clinicians probing the
intricacies of the MR, and the clinical benefits that accrue
from MRA.
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